摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-fluoro-6-<<(4-methylphenyl)sulfonyl>oxy>benzisoquinoline-5,10-dione | 156090-75-4

中文名称
——
中文别名
——
英文名称
9-fluoro-6-<<(4-methylphenyl)sulfonyl>oxy>benzisoquinoline-5,10-dione
英文别名
9-fluoro-5,10-dioxo-5,10-dihydrobenzo[g]isoquinolin-6-yl tosylate;9-fluoro-6-(p-toluenesulfonyloxy)benzo[g]isoquinoline-5,10-dione;(9-fluoro-5,10-dioxobenzo[g]isoquinolin-6-yl) 4-methylbenzenesulfonate
9-fluoro-6-<<(4-methylphenyl)sulfonyl>oxy>benz<g>isoquinoline-5,10-dione化学式
CAS
156090-75-4
化学式
C20H12FNO5S
mdl
——
分子量
397.383
InChiKey
QFMCLDGPDNLZEA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    634.5±55.0 °C(Predicted)
  • 密度:
    1.491±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    28
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    98.8
  • 氢给体数:
    0
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    9-fluoro-6-<<(4-methylphenyl)sulfonyl>oxy>benzisoquinoline-5,10-dione吡啶三乙胺 作用下, 以 四氢呋喃 为溶剂, 反应 9.0h, 生成 2-<2-<(methylsulfonyl)oxy>ethyl>-5-<<2-<(methylsulfonyl)oxy>ethyl>amino>indazolo<4,3-gh>isoquinolin-6(2H)-one
    参考文献:
    名称:
    Paul Krapcho, Journal of Medicinal Chemistry, 1998, vol. 41, # 27, p. 5429 - 5444
    摘要:
    DOI:
  • 作为产物:
    描述:
    9-Fluoro-6-hydroxybenzo[g]isoquinoline-5,10-dione 以78的产率得到9-fluoro-6-<<(4-methylphenyl)sulfonyl>oxy>benzisoquinoline-5,10-dione
    参考文献:
    名称:
    J. Med. Chem. 1998, 41, 5429-5444
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • 2-aminoalkyl-5-aminoalkylamino substituted-isoquinoindazole-6(2H)-ones
    申请人:Boehringer Mannheim Italia, S.p.A.
    公开号:US05519029A1
    公开(公告)日:1996-05-21
    This invention is directed to 2-aminoalkyl-5-aminoalkylamino substituted isoquino [8,7,6-cd]indazole-6-(2H)-ones and to 2-aminoalkyl-5-aminoalkylamino substituted-isoquino [5,6,7-cd] indazole-6(2H)-ones. These compounds have been shown to have antitumor activity.
    这项发明涉及2-氨基烷基-5-氨基烷基氨基取代的异喹诺[8,7,6-cd]吲哚-6-(2H)-酮和2-氨基烷基-5-氨基烷基氨基取代的异喹诺[5,6,7-cd]吲哚-6(2H)-酮。这些化合物已被证明具有抗肿瘤活性。
  • Hetero-annulated indazoles
    申请人:The University of Vermont
    公开号:US05596097A1
    公开(公告)日:1997-01-21
    This invention is directed to heteroannulated indazoles namely to 2,5-disubstituted quinolino-, isoquinolino-, phthalazino-, and quinoxalino- annulated indazole-6(2H)-ones and related mono N-oxides. These compounds have been shown to have antitumor activity.
    这项发明涉及杂环并联吲唑,特别是2,5-二取代喹啉基、异喹啉基、邻苯二氮杂环基和喹啉基并联的吲唑-6(2H)-酮及相关的单N-氧化物。这些化合物已被证明具有抗肿瘤活性。
  • Synthesis and Antitumor Evaluation of Bis Aza-anthracene-9,10-diones and Bis Aza-anthrapyrazole-6-ones
    作者:Ippolito Antonini、Giorgio Santoni、Roberta Lucciarini、Consuelo Amantini、Diego Dal Ben、Rosaria Volpini、Gloria Cristalli
    DOI:10.1021/jm7013937
    日期:2008.2.1
    The good results obtained as potential antitumor drugs with aza-anthracenediones and aza-anthrapyrazoles, e.g. pixantrone, 1a, and 1b (Chart 1), prompted us to design and synthesize a series of symmetrical bis derivatives, compounds 7-10 (Chart 1). These compounds are dimers of different aza-anthracenedione and aza-anthrapyrazolone monomers connected by the linker found to be the most appropriate among potential bis intercalators synthesized by us. The DNA-binding properties of bis derivatives 7 and 8 have been examined using fluorometric techniques: these target compounds are excellent DNA ligands, with a clear binding site preference for AT-rich duplexes. In vitro cytotoxic activity of all target compounds 7-10 and of reference compound pixantrone toward human cancer adenocarcinoma cell line HT29 is also described. Two selected compounds have been investigated for their capacity of inducing early apoptosis.
  • 2-AMINOALKYL-5-AMINOALKYLAMINO SUBSTITUTED ISOQUINOINDAZOLE-6-(2H)-ONES WITH ANTITUMOUR ACTIVITY
    申请人:THE UNIVERSITY OF VERMONT
    公开号:EP0662076B1
    公开(公告)日:2001-04-11
  • HETERO-ANNULATED INDAZOLES
    申请人:Novuspharma S.p.A.
    公开号:EP0750619B1
    公开(公告)日:2001-05-30
查看更多